SNTI (Senti Biosciences Holdings) Moat Score: 3/10 (As of Jul. 12, 2026)


SNTI Senti Biosciences Holdings Inc SNTI
22 GF Score
Price $1.03
! 7 Warning Signs
View Full Analysis

What is Senti Biosciences Holdings Moat Score?

Senti Biosciences Holdings SNTI +3.00% 22 Moat Score is 3 as of Jul. 12, 2026. GuruFocus rates SNTI with a GF Score™ of 22/100. The stock has 7 warning signs investors should review. Among 1,396 Biotechnology companies, Senti Biosciences Holdings ranks better than 75.57% on this metric.

Senti Biosciences Holdings has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Senti Biosciences Holdings has No Moat: Senti Biosciences Holdings Inc has very weak competitive advantages. It is in the early stages of development with limited market presence and lacks significant intellectual property or regulatory barriers. The company's moat is currently very weak and transient.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Senti Biosciences Holdings might have No Moat - Very weak/transient advantages.

Senti Biosciences Holdings  (NAS:SNTI) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Senti Biosciences Holdings Moat Score Related Terms

SNTI vs ALGS, CRVO, NTRB: Moat Score Comparison

For the Biotechnology subindustry, Senti Biosciences Holdings's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Senti Biosciences Holdings Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Senti Biosciences Holdings's Moat Score distribution charts can be found below:

* The bar in red indicates where Senti Biosciences Holdings's Moat Score falls into.


SNTI
22GF Score
Senti Biosciences Holdings Inc SNTI
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Senti Biosciences Holdings (SNTI) has a Moat Score of 3 as of Jul. 12, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Senti Biosciences Holdings ranks #341 out of 1396 companies in the Biotechnology industry, placing it in the top 24.4%.
Is Senti Biosciences Holdings' Moat Score too high?
Senti Biosciences Holdings' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Senti Biosciences Holdings' value of 3 is 50% above this industry median. Based on the distribution chart, Senti Biosciences Holdings ranks #341 out of 1396 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Senti Biosciences Holdings has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Senti Biosciences Holdings' Moat Score compare to ALGS and CRVO?
According to the Biotechnology industry distribution chart, Senti Biosciences Holdings ranks #341 out of 1396 companies for Moat Score. This places Senti Biosciences Holdings in the top 24% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Senti Biosciences Holdings' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,396 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Senti Biosciences Holdings's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Senti Biosciences Holdings's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senti Biosciences Holdings stock overvalued right now?
Senti Biosciences Holdings (SNTI) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Senti Biosciences Holdings' overall GF Score™ is 22/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Senti Biosciences Holdings (SNTI), the current Moat Score is 3 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Senti Biosciences Holdings Business Description

Address 2 Corporate Drive, First Floor, South San Francisco, CA, USA, 94080
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).
22GF Score

Get the complete analysis for SNTI

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.03
Price